European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination
Open accessAbstract
In a project coordinated by the International Agency for Research on Cancer (IARC) 31 experts from 11 European countries and IARC have developed supplements to the current European guidelines for quality assurance in cervical cancer screening. The supplements take into account the potential of primary testing for human papillomavirus (HPV) and vaccination against HPV infection to improve cervical cancer prevention and control and will be published by the European Commission in book format. They include 62 recommendations or conclusions for which the strength of the evidence and the respective recommendations is graded. While acknowledging the available evidence for more efficacious screening using HPV primary testing compared to screening based on cytology, the authors and editors of the supplements emphasize that appropriate policy and programme organization remain essential to achieve an acceptable balance between benefit and harm of any screening or vaccination programme. A summary of the supplements and all of the graded recommendations are presented here in journal format to make key aspects of the updated and expanded guidelines known to a wider professional and scientific community.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
HPV DNA testing is recommended by WHO, the US Preventive Services Task Force and Australian, US and European national screening programme guidelines as an effective approach for the early detection of cervical cancer for women aged 30 years and older.
“HPV DNA testing is recommended by WHO, the US Preventive Services Task Force and Australian, US and European national screening programme guidelines as an effective approach for the early detection of cervical cancer for women ≥30 years.7–9”
From HPV self-sampling for cervical cancer screening: a systematic review of values and preferences (2021) · cites this paper as [8]
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 41 · Cited by 253
Research works printed but not linked: 10
- [2]Anttila A. Ronco G. Nicula F. Nieminen P. Primic Žakelj M. Organization of cytology-based or HPV-based cervical cancer screening. S2 Anttila A. Arbyn A. De Vuyst H. Dillner J. Dillner L. Franceschi S. Patnick J. Ronco G. Segnan N. Suonio E. Törnberg S. von Karsa L. European Guidelines for Quality Assurance in Cervical Cancer Screening second edition, Supplements 2015 Office for Official Publications of the European Union Luxembourg (in press)
- [4]Arbyn M. Anttila A. Jordan J. Schenck U. Ronco G. Segnan N. Wiener H. Herbert A. Daniel J. von Karsa L. European Guidelines for Quality Assurance in Cervical Cancer Screening second edition 2008 European Commission, Office for Official Publications of the European Communities Luxembourg
- [11]De Vuyst H. Howell-Jones R. Levy-Bruhl D. Giorgi Rossi P. Franceschi S. Implementation of vaccination against human papillomavirus in Europe. S3 Anttila A. Arbyn M. De Vuyst H. Dillner J. Dillner L. Franceschi S. Patnick J. Ronco G. Segnan N. Suonio E. Törnberg S. von Karsa L. European Guidelines for Quality Assurance in Cervical Cancer Screening second edition, Supplements 2015 Office for Official Publications of the European Union Luxembourg (in press)
- [18]T. Greenhalgh, Why read papers at all? In: How to Read a Paper: The Basics of evidence-Based Medicine, BMJ Publishing Group, London, 1997, pp. 1–14.
- [19]IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 100B: A Review of Human Carcinogens: Biological Agents 2012 International Agency for Research on Cancer Lyon
- [30]O’Connor D. Green S. Higgins J.P.T. Defining the review question and developing criteria for including studies Higgins J.P.T. Green S. Cochrane Handbook for Systematic Reviews of Interventions (Wiley Cochrane Series) 2008 Wiley-Blackwell UK
- [34]Ronco G. Arbyn M. CJLM Meijer Snijders P.J.F. Cuzick J. Screening for cervical cancer with primary testing for human papillomavirus. S1 Anttila A. Arbyn A. De Vuyst H. Dillner J. Dillner L. Franceschi S. Patnick J. Ronco G. Segnan N. Suonio E. Törnberg S. von Karsa L. European Guidelines for Quality Assurance in Cervical Cancer Screening second edition, Supplements 2015 Office for Official Publications of the European Union Luxembourg (in press)
- [41]N. Segnan, J. Patnick, L. von Karsa, (Eds.), European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis, in: first edition, European Commission, Office for Official Publications of the European Union, Luxembourg, 2010
- [43]von Karsa L. Anttila A. Primic Žakelj M. de Wolf C. Bielska-Lasota M. Törnberg S. Segnan N. Stockholm statement on successful implementation of population-based cancer screening programmes. Annex 1a Perry N. Broeders M. de Wolf C. Törnberg S. Holland R. von Karsa L. European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis fourth edition, Supplements 2013 European Commission, Office for Official Publications of the European Union Luxembourg 123 128
- [45]von Karsa L. Qiao Y.-L. Ramadas K. Keita N. Arrossi S. Dean P.B. Al Alwan N. Sankaranarayanan R. Screening—implementation, Chapter 4.8 Stewart B.W. Wild C.P. World Cancer Report 2014 2014 International Agency for Research on Cancer Lyon 330 336
- Authors
- von Karsa, L., Arbyn, M., De Vuyst, H., Dillner, J., Dillner, L., Franceschi, S., Patnick, J., Ronco, G., Segnan, N., Suonio, E., Törnberg, S., & Anttila, A.
- Affiliations
- Institut Scientifique de Santé Publique (BE)
- Karolinska Institutet (SE)
- Karolinska University Hospital (SE)
- Centre international de recherche sur le cancer (FR)
- Public Health England (GB)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Finnish Cancer Registry (FI)
- ORCID
- Venue
- Papillomavirus Research
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 1
- Pages
- 22-31
- ISSN
- 2405-8521 (ISSN-L)
- PMC
- PMC5886856
- OpenAlex
- W771312976
- Cited by
- 253
- References
- 41
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 32 · 2023: 21 · 2022: 25 · 2021: 38 · 2020: 28 · 2019: 27 · 2018: 20 · 2017: 10 · 2016: 21 · 2015: 7 · 2013: 1
- FWCI
- 15.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Papillomavirus Research (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- European Union Public Health Programme (2006 322)
- Topics
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- cervical cancer screening, quality assurance, HPV vaccination, cervical cancer prevention, cytology-based screening, screening guidelines, benefit-harm balance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
